Gastrointestinal Therapeutics Market Report 2026

The gastrointestinal therapeutics market size has grown strongly in recent years. It will grow from $42.3 billion in 2025 to $44.72 billion in 2026 at a compound annual growth rate (CAGR) of 5.7%. The growth in the historic period can be attributed to limited availability of biologics and advanced gastrointestinal therapies, increasing incidence of acid reflux and ulcers, reliance on hospital and clinic-based treatment, growing awareness of digestive health, dominance of traditional otc antacids and laxatives.

The gastrointestinal therapeutics market size is expected to see strong growth in the next few years. It will grow to $55.21 billion in 2030 at a compound annual growth rate (CAGR) of 5.4%. The growth in the forecast period can be attributed to development of targeted biologics and immunotherapies, expansion of ambulatory surgical centers and diagnostic laboratories, rising adoption of oral and intravenous delivery systems, increasing online pharmacy penetration, innovation in probiotics and digestive enzyme formulations. Major trends in the forecast period include rising prevalence of gastrointestinal disorders, increased adoption of biologics and advanced therapies, expansion of over-the-counter therapeutics, growing focus on personalized gastrointestinal treatments, rising online and retail pharmacy distribution.

The increasing prevalence of inflammatory bowel diseases is anticipated to drive the growth of the gastrointestinal therapeutics market in the coming years. Inflammatory bowel disease (IBD) is a chronic disorder characterized by inflammation of the digestive tract, mainly encompassing Crohn’s disease and ulcerative colitis. The rising incidence of inflammatory bowel diseases is attributed to genetic susceptibility, which leads to an abnormal immune response to gut microbes. Gastrointestinal therapeutics support the management and treatment of bowel diseases by targeting underlying inflammation, regulating digestive processes, and relieving associated symptoms to improve patient outcomes. For instance, in December 2023, according to the IBD Registry, a UK-based non-profit organization, more than 5,300 individuals with inflammatory bowel diseases (IBD) were registered in 2023, representing an increase of over 3,000 members compared to 2022. Therefore, the growing prevalence of inflammatory bowel diseases is contributing to the expansion of the gastrointestinal therapeutics market.

Key companies operating in the gastrointestinal therapeutics market are concentrating on the development of innovative therapies, such as sustained-release (SR) fixed-dose combination capsules, to enhance patient adherence and improve treatment efficacy. Sustained-release (SR) fixed-dose combination capsules are oral formulations designed to slowly release multiple active ingredients over time, ensuring stable drug levels and reducing dosing frequency. For example, in June 2024, Akums Drugs and Pharmaceuticals Limited, an India-based pharmaceutical preparation manufacturing company, introduced rabeprazole and levosulpiride SR capsules for the treatment of gastrointestinal disorders in India. This formulation combines rabeprazole, a proton pump inhibitor that reduces gastric acid secretion, with levosulpiride, a prokinetic agent that enhances gut motility. Together, these components provide effective relief from symptoms such as heartburn, acid reflux, bloating, and indigestion. This combination therapy is commonly prescribed for managing gastroesophageal reflux disease, peptic ulcers, and other related gastrointestinal (GI) conditions.

In April 2023, Merck & Co., Inc., a US-based pharmaceutical company, acquired Prometheus Biosciences, Inc. for $10.8 billion. Through this acquisition, Merck & Co., Inc. aimed to strengthen its immunology pipeline by advancing precision-based therapies for inflammatory conditions such as ulcerative colitis and Crohn’s disease. Prometheus Biosciences, Inc. is a US-based biotechnology company focused on the development of precision therapeutics for immune-mediated diseases, particularly gastrointestinal disorders.

Major companies operating in the gastrointestinal therapeutics market are Abbott Laboratories, Novartis AG, Takeda Pharmaceutical Company Limited., Boehringer Ingelheim International GmbH, Otsuka Holdings Co. Ltd., Daiichi Sankyo Company Limited., Bausch Health Companies Inc, UCB S.A., Eisai Co. Ltd., Aurobindo Pharma Limited., Dr. Reddy’s Laboratories Limited., Ironwood Pharmaceuticals Inc, Salix Pharmaceuticals Ltd., Ferring Pharmaceuticals A/S, Jubilant Pharma Limited., Sebela Pharmaceuticals Inc, Cosmo Pharmaceuticals N.V., Tillotts Pharma AG, Mitsubishi Tanabe Pharma Corporation.

North America was the largest region in the gastrointestinal therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastrointestinal therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the gastrointestinal therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the gastrointestinal therapeutics market by increasing the cost of imported raw materials, active pharmaceutical ingredients, and biologics, especially for prescription-based therapeutics. Segments such as proton pump inhibitors, biologics, and aminosalicylates are most impacted, with regions like North America and Asia-Pacific facing higher import duties. While tariffs have led to increased production costs and price adjustments, they have also encouraged local manufacturing, innovation in drug formulations, and enhanced domestic supply chain resilience.

The gastrointestinal therapeutics market research report is one of a series of new reports that provides gastrointestinal therapeutics market statistics, including gastrointestinal therapeutics industry global market size, regional shares, competitors with a gastrointestinal therapeutics market share, detailed gastrointestinal therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the gastrointestinal therapeutics industry. This gastrointestinal therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Gastrointestinal therapeutics encompass a variety of drugs, biologics, and treatment options used to prevent, manage, or treat disorders of the gastrointestinal tract, including the esophagus, stomach, intestines, liver, pancreas, and gallbladder. These therapies address conditions such as acid reflux, ulcers, irritable bowel syndrome, Crohn’s disease, and gastrointestinal cancers.

The primary product categories of gastrointestinal therapeutics include over-the-counter gastrointestinal therapeutics and prescription-based gastrointestinal therapeutics. Over-the-counter gastrointestinal therapeutics are non-prescription medications intended to relieve common digestive problems such as heartburn, indigestion, gas, constipation, and diarrhea. These therapies are delivered through different routes of administration, including oral, intravenous, and others. They are applied across various indications, including inflammatory bowel disease, gastroesophageal reflux disease, peptic ulcer disease, irritable bowel syndrome, and others. The products are distributed via several channels, such as hospital pharmacies, retail pharmacies, and online pharmacies, and are used by diverse end users including hospitals, clinics, ambulatory surgical centers, diagnostic laboratories, and others.

The gastrointestinal therapeutics market consists of sales of acid suppressants, antiemetic agents, antispasmodics, digestive enzymes, and prebiotics and probiotics. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.